Core Insights - Royal Philips has launched Verida, the world's first detector-based spectral CT fully powered by AI, marking a significant advancement in CT technology [1][6] - The integration of AI optimizes the imaging chain, resulting in lower system noise, improved image quality, and enhanced clinical workflow [1][3] Company Overview - Philips is a global leader in health technology, focusing on improving health and well-being through innovation [12] - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people across more than 100 countries [13] Product Features - Verida utilizes AI to enhance spectral image quality and reduce noise, achieving a dose reduction of up to 45% without compromising image quality [3][6] - The system can reconstruct 145 images per second, allowing for exams to be completed in under 30 seconds, effectively doubling the speed of previous systems [4][10] - Verida is designed for high-demand environments, streamlining workflows and reducing the need for repeat scans while delivering consistent imaging quality [6] Clinical Impact - The introduction of Verida is expected to change the approach to cardiac imaging, providing comprehensive insights and potentially reducing the need for invasive procedures [4][5] - Philips' spectral CT technology has been widely adopted in clinical settings, supported by over 800 peer-reviewed publications [2][7] Market Position - Philips' spectral CT has been a reliable clinical tool for over a decade, offering comparable or superior clinical outcomes at a lower total cost of ownership compared to photon-counting CT systems [5][6] - Verida will be available in select markets starting in 2026, further solidifying Philips' position in the health technology sector [6]